Advanced	B:C1999167
age	I:C1999167
is	O
not	O
a	O
barrier	O
to	O
creating	O
a	O
functional	O
arteriovenous	O
fistula	I:C1541850
:	O
a	O
retrospective	O
study	I:C0035363
.	O

Advanced	O
age	I:C1999167
is	O
not	O
a	O
barrier	O
to	O
creating	O
a	O
functional	O
arteriovenous	B:C1541850
fistula	I:C1541850
:	O
a	O
retrospective	O
study	I:C0035363
.	O

Advanced	O
age	I:C1999167
is	O
not	O
a	O
barrier	O
to	O
creating	O
a	O
functional	O
arteriovenous	O
fistula	I:C1541850
:	O
a	O
retrospective	B:C0035363
study	I:C0035363
.	O

Arteriovenous	B:C1541850
fistulas	I:C1541850
(	O
Arteriovenous	O
fistulas	I:C1541850
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	O
access	O
for	O
hemodialysis	O
.	O

Arteriovenous	O
fistulas	I:C1541850
(	O
Arteriovenous	B:C1541850
fistulas	I:C1541850
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	O
access	O
for	O
hemodialysis	O
.	O

Arteriovenous	O
fistulas	I:C1541850
(	O
Arteriovenous	O
fistulas	I:C1541850
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	O
access	O
for	O
hemodialysis	B:C0019004
.	O

However	O
,	O
controversy	O
exists	O
regarding	O
whether	O
Arteriovenous	B:C1541850
fistulas	I:C1541850
are	O
suitable	O
for	O
elderly	O
patients	O
.	O

However	O
,	O
controversy	O
exists	O
regarding	O
whether	O
Arteriovenous	O
fistulas	I:C1541850
are	O
suitable	O
for	O
elderly	B:C0001792
patients	O
.	O

Single	B:C0035363
-	I:C0035363
center	I:C0035363
retrospective	I:C0035363
review	I:C0035363
to	O
investigate	O
the	O
impact	O
of	O
age	O
on	O
AVF	O
outcomes	O
.	O

Single	O
-	I:C0035363
center	I:C0035363
retrospective	I:C0035363
review	I:C0035363
to	O
investigate	O
the	O
impact	O
of	O
age	O
on	O
AVF	B:C1541850
outcomes	O
.	O

Five	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	O
with	O
AVF	B:C1541850
creation	O
were	O
stratified	O
based	O
on	O
age	O
<	O
65	O
,	O
65	O
-	O
75	O
,	O
and	O
>	O
75	O
years	O
.	O

AVF	B:C1541850
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	O
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	O
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	O
creation	O
.	O

AVF	O
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	B:C1541850
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	O
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	O
creation	O
.	O

AVF	O
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	O
patency	B:C0042377
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	O
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	O
creation	O
.	O

AVF	O
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	O
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	B:C1541850
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	O
creation	O
.	O

AVF	O
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	O
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	O
complications	B:C0009566
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	O
creation	O
.	O

AVF	O
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	O
patency	O
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	O
complications	O
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	B:C1541850
creation	O
.	O

The	O
cohort	B:C0599755
was	O
63	O
%	O
male	O
,	O
44	O
%	O
Caucasian	O
,	O
and	O
55	O
%	O
had	O
diabetes	O
or	O
cardiovascular	O
disease	I:C0007222
.	O

The	O
cohort	O
was	O
63	O
%	O
male	B:C0025266
,	O
44	O
%	O
Caucasian	O
,	O
and	O
55	O
%	O
had	O
diabetes	O
or	O
cardiovascular	O
disease	I:C0007222
.	O

The	O
cohort	O
was	O
63	O
%	O
male	O
,	O
44	O
%	O
Caucasian	B:C0043157
,	O
and	O
55	O
%	O
had	O
diabetes	O
or	O
cardiovascular	O
disease	I:C0007222
.	O

The	O
cohort	O
was	O
63	O
%	O
male	O
,	O
44	O
%	O
Caucasian	O
,	O
and	O
55	O
%	O
had	O
diabetes	B:C0011847
or	O
cardiovascular	O
disease	I:C0007222
.	O

The	O
cohort	O
was	O
63	O
%	O
male	O
,	O
44	O
%	O
Caucasian	O
,	O
and	O
55	O
%	O
had	O
diabetes	O
or	O
cardiovascular	B:C0007222
disease	I:C0007222
.	O

No	O
differences	O
in	O
rates	O
of	O
primary	O
failure	O
,	O
loss	O
of	O
primary	O
patency	B:C0042377
,	O
complications	O
,	O
or	O
need	O
for	O
intervention	O
were	O
observed	O
between	O
age	O
groups	O
.	O

No	O
differences	O
in	O
rates	O
of	O
primary	O
failure	O
,	O
loss	O
of	O
primary	O
patency	O
,	O
complications	B:C0009566
,	O
or	O
need	O
for	O
intervention	O
were	O
observed	O
between	O
age	O
groups	O
.	O

No	O
differences	O
in	O
rates	O
of	O
primary	O
failure	O
,	O
loss	O
of	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
need	O
for	O
intervention	B:C0184661
were	O
observed	O
between	O
age	O
groups	O
.	O

There	O
was	O
a	O
significant	O
association	O
of	O
age	O
with	O
secondary	O
patency	B:C0042377
and	O
functional	O
patency	O
,	O
with	O
age	O
>	O
75	O
being	O
an	O
independent	O
risk	O
factor	I:C0035648
for	O
shortened	O
lifespan	O
of	O
the	O
fistula	O
.	O

There	O
was	O
a	O
significant	O
association	O
of	O
age	O
with	O
secondary	O
patency	O
and	O
functional	O
patency	B:C0042377
,	O
with	O
age	O
>	O
75	O
being	O
an	O
independent	O
risk	O
factor	I:C0035648
for	O
shortened	O
lifespan	O
of	O
the	O
fistula	O
.	O

There	O
was	O
a	O
significant	O
association	O
of	O
age	O
with	O
secondary	O
patency	O
and	O
functional	O
patency	O
,	O
with	O
age	O
>	O
75	O
being	O
an	O
independent	O
risk	B:C0035648
factor	I:C0035648
for	O
shortened	O
lifespan	O
of	O
the	O
fistula	O
.	O

For	O
patients	O
aged	O
>	O
75	O
years	O
,	O
secondary	O
patency	B:C0042377
at	O
3	O
years	O
was	O
64	O
%	O
compared	O
to	O
75	O
%	O
-	O
78	O
%	O
for	O
younger	O
patients	O
.	O

Functional	O
patency	B:C0042377
at	O
2	O
years	O
was	O
69	O
%	O
for	O
those	O
aged	O
>	O
75	O
years	O
compared	O
to	O
78	O
%	O
-	O
81	O
%	O
for	O
younger	O
patients	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	B:C1541850
maturation	O
,	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
interventions	O
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	O
maturation	B:C1254042
,	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
interventions	O
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	O
maturation	O
,	O
primary	O
patency	B:C0042377
,	O
complications	O
,	O
or	O
interventions	O
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	O
maturation	O
,	O
primary	O
patency	O
,	O
complications	B:C0009566
,	O
or	O
interventions	O
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	O
maturation	O
,	O
primary	O
patency	O
,	O
complications	O
,	O
or	O
interventions	B:C0184661
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

While	O
secondary	O
and	O
functional	O
patency	B:C0042377
rates	O
were	O
significantly	O
lower	O
in	O
those	O
aged	O
>	O
75	O
years	O
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O

Therefore	O
,	O
we	O
recommend	O
that	O
advanced	B:C1999167
age	I:C1999167
alone	O
should	O
not	O
preclude	O
patients	O
from	O
AVF	O
creation	O
.	O

Therefore	O
,	O
we	O
recommend	O
that	O
advanced	O
age	I:C1999167
alone	O
should	O
not	O
preclude	O
patients	O
from	O
AVF	B:C1541850
creation	O
.	O

